Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patients with non valvular atrial fibrillation and any of the following:

-

• 60 years old with heart disease but no risk factors.

• >/=60 years old and
• Must be able to take aspirin.

Exclusion Criteria:

• Previous heart attack or stroke.

• History of high blood pressure, diabetes or a prior blood clot.

• Liver or kidney disease.

• Need for anti-thrombotic or anti-platelet drugs.

• Need for cardiovascular medicines.